This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Urinary incontinence and hormone replacement therapy (HRT)

Authoring team

  • previously HRT was considered a treatment option. However results from the Women's Health Initiative revealed that HRT was associated with increased incidence and severity of urinary incontinence (UI) (1)
    • the authors concluded that conjugated equine estrogen (CEE) alone and CEE + medroxyprogesterone acetate (MPA) increased the risk of UI among continent women and worsened the characteristics of UI among symptomatic women after 1 year. Conjugated equine estrogen with or without progestin should not be prescribed for the prevention or relief of UI
  • the WHI study results confirmed earlier findings of the HERS trial (2)

Reference:

  1. Hendrix SL et al. Effects of estrogen with and without progrestin on urinary incontinence. JAMA 2005; 293:935-48
  2. Grady D et al.Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-20

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.